Akebia Therapeutics Inc. buy BTIG Research
Start price
02.12.25
/
50%
€1.27
Target price
02.12.26
€4.31
Performance (%)
-12.68%
Price
05.08.26
€1.12
Summary
This prediction is currently active. The price of Akebia Therapeutics Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -12.68%. This prediction currently runs until 02.12.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 1.958% | 1.958% |
| iShares Core DAX® | 3.153% | 1.504% |
| iShares Nasdaq 100 | 7.431% | -1.584% |
| iShares Nikkei 225® | 8.571% | -4.324% |
| iShares S&P 500 | 4.578% | 1.920% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.18
07.04.26
07.04.26
€3.47
07.04.27
07.04.27
-4.80%
05.08.26
05.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
3.39%
05.08.26
05.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.93
29.10.25
29.10.25
€4.29
29.10.26
29.10.26
-42.30%
05.08.26
05.08.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24